This study examined trends in stimulant use and attitudes toward use among American collegiate hockey athletes. All 139 players in one college hockey conference completed a comprehensive questionnaire. Over half of the athletes (51.8%) confi rmed stimulant use before a hockey game or practice. About half of the respondents (48.5%) reported having used ephedra at least one time to improve athletic performance. Additionally, 17.4% reported using pseudoephedrine to improve performance in the 30 days prior to survey administration. Over half (55.4%) were aware of the recent national ban on ephedra. Fifty-nine percent stated the national ban made them less likely to use ephedra products. The majority of athletes began use prior to college. Coaches, athletic trainers, and team physicians should be aware of athletesʼ patterns of stimulant use. Improved educational efforts directed at younger athletes are necessary to deter abuse of metabolic stimulants.
Athletes have been noted to utilize ephedrine, ephedra, and other sympathomimetic agents to enhance performance (1) . The popularity of these agents led the National Collegiate Athletic Association (NCAA) to institute a ban on ephedrine in 1997 (11) . Further alarming trends led the U.S. Food and Drug Administration (FDA) to initiate a national ban on the sale of over-the-counter products containing ephedra in 2004 (12) .
There have been few studies detailing prevalence of use, attitudes, and knowledge of stimulants among collegiate athletes. Prior research demonstrated a 3.0 to 3.4% prevalence of ephedrine use among a general population of college athletes (11, 15) . Eleven percent of hockey athletes reported recent use of ephedrine in 2003 (1) . No study has addressed the age of onset of stimulant use.
Our purpose was to better defi ne the spectrum of stimulant use in college hockey players. We included questions assessing knowledge of side effects and attitudes regarding the recent national ban. We also sought to determine the average age of initial stimulant use in order to better target education efforts.
Methods
We studied one male NCAA Division I hockey conference at the 2004 championship. Each of the six teams in the conference participated in the end-of-season tournament. A preliminary study was administered with similar methods at the 2003 championship tournament (1) . Athletic trainers for each team were contacted prior to the tournament and agreed to assist in the administration of the survey. Each survey was accompanied by a cover letter ensuring the confi dentiality and anonymity of each player and school. The athletic trainers administered the one-page survey prior to a team meeting or practice. The athletes placed the completed surveys in plain envelopes and returned them to the athletic trainers.
Survey Instrument
The survey was modifi ed from our preliminary study (1) , with additional questions regarding patterns of use. Questions relating to the FDA ban on ephedra were added, as well as questions regarding patterns of stimulant use. The survey was reviewed and approved by the U.S. Air Force Academy Institutional Review Board prior to administration. There were 27 questions in the survey, divided into 3 sections. The fi rst section included demographic questions. Nationality was attained from the team rosters in order to maintain survey anonymity. The second section queried about stimulant use. The athlete was asked to circle whether they had taken a specifi ed stimulant in the past 30 days, prior to the past 30 days or never. Specifi c questions regarding ephedrine included an explanation that for the purposes of this study ephedrine, ephedra, and ma huang were considered equivalent. Further questions examined use of amphetamines, pseudoephedrine, and caffeine. We included brand names next to the generic names such as Ripped Fuel (Twin Lab, Hauppauge, NY), Hydroxycut (MuscleTech, Mississauga, Ontario), and Xenadrine (Cytodyne Technologies, Hicksville, NY) as examples of ephedrine-containing products. Sudafed (Pfi zer, NY, NY) and Actifed (Pfi zer) were used as examples of psuedoephedrine-containing products to assist with recognition.
The third section in the survey contained knowledge and attitude questions. Knowledge questions were derived from side effects documented in the literature (6, 12, 16, 17) . The athletes were asked to mark 1 of 7 circles on a 7-point Likert scale of agreement. The athlete marked a circle ranging from strongly disagree to strongly agree. For certain questions, responses were recoded to binary variables using 1-4 (strongly disagree to neutral) as no agreement and 5-7 as agreement. The average survey completion time was approximately 10 to15 min.
Data were tabulated using Excel (Microsoft, Redmond, WA), and statistical analysis was performed in SPSS. Formal statistical analyses were used to calculate confi dence intervals and to compare responses between groups of ephedrine users and nonusers. For binary data, the large sample normal approximation was used to compute standard errors for proportions. Studentʼs two-sample t-test was used to compare means for interval data, while confi dence intervals were estimated using large sample normal theory.
Results
One hundred thirty-nine players completed and returned the survey. This corresponded to all players (100%) on each of the six teamsʼ rosters at the 2004 conference championship. The average age was 21.6 years and 92.1% played junior hockey prior to college. Seventy-three percent were listed as foreign-born players on the team rosters.
Patterns of Ephedra Use
In this study, 48.5% of players admitted to using ephedra at some point to enhance performance (Table 1) , with an estimated 95% confi dence interval of 40.6% to 57.2%. Among those admitting to ephedra use, 8.8% stated they had taken it in the last month, and 8.8% said they had last taken ephedra 2 to 6 months ago ( Table  2 ). The majority (89.7%) of those reporting ephedra use fi rst took it prior to college. The most common reason given for using ephedra was for more energy for games ( Table 2 ).
Other Stimulants
Results in Table 3 illustrate that about half of the respondents have used energy drinks and/or caffeine at some point to improve performance. Twelve percent admitted to using diet pills at some point to enhance athletic performance, and 3.6% admitted to amphetamine use for this purpose. The most commonly used stimulant other than caffeine or energy drinks was psuedoephedrine. Forty-four percent of respondents indicated they have used pseudoephedrine to enhance athletic performance, with 17.4% of respondents reporting use within the prior 30 days.
Participants were queried about their general use of stimulants to get energy before a hockey game or practice (Table 4) . Over half the respondents (51.8%) have used some type of stimulant to get energy before hockey games or practice. Over 21% admitted to using a stimulant at least weekly, 7.2% monthly, and 23% have used stimulants only one or twice for this purpose. 
Knowledge
Using the Likert scale of agreement (1 = strongly disagree, 7 = strongly agree), a majority of athletes agreed (71.9%) that the potential adverse effects of ephedrine could cause increased blood pressure and 71.2% of respondents agreed that side effects could cause potential sleep disturbance. Just over half (50.4%) agreed that sudden death could be caused by ephedrine use, and 59.7% agreed that a heart attack could result from use of ephedrine (Table 5) . 
Beliefs and Attitudes
The majority of athletes (80.3%) were aware of the NCAA ban on ephedrine and 55.4% were aware of the national ban on ephedra (Table 5 ). Forty percent of athletes admitted they would take a banned substance if it would help them play at a higher level of hockey (American or National Hockey League). Fifty-nine percent of the respondents agreed that the national ban on ephedra made them less likely to use ephedra, while 13% disagreed with this statement. Twenty-eight percent of players provided neutral responses (neither agreed nor disagreed) to this question. Respondents were asked the percentage of male athletes at their school that they thought had used an NCAA-banned substance. Of the respondents who reported no ephedra use, the average perceived percentage of athletes who have used a banned substance was 22.6% (Table 6 ). For respondents who admitted ephedra use, the average percentage was 41.1%. This difference in perceived use of ephedra by other athletes was statistically signifi cant with P < .001.
Discussion
Athletes have used ergogenic aids to maximize performance for decades (10) . Previous epidemiologic research has centered primarily on anabolic steroids (7-9). More recently, ephedrine and other stimulants have garnered national attention (1, 15) . Popular media coverage of high profi le athletesʼ deaths attributed to stimulants raised national concern. There has been little scientifi c research dedicated to patterns of use of ephedrine, pseudoephedrine, and other stimulants.
One large study of athletes completed in 1997 showed a 3.0% overall rate of NCAA athletesʼ use of ephedrine (11) . Four percent of the questionnaires returned were from hockey athletes, and 3.9% of these hockey players reported previous ephedrine use. A related study showed 3.4% rate of ephedrine use among NCAA athletes in 2001 (15) . In hockey athletes surveyed in 2003, 38% stated they had used ephedrine at some point with 11% admitting use within the past 30 days (1).
The current study showed over half of the players in one hockey conference have used a stimulant to enhance athletic performance. These numbers may reveal a trend toward increased use or may be the result of more targeted questions regarding specifi c ergogenic aids.
The potential use of stimulants requires close scrutiny by trainers and team physicians due to a number of adverse events associated with their use. Reactions reported from ephedrine use range from nervousness, dizziness, tremor, alterations in blood pressure or heart rate to chest pain, myocardial infarction, stroke, seizures, psychosis, and death (12, 16, 17) . Of concern is that these events have been reported in healthy individuals of all age groups (6, 12, 16) . Athletes may feel pseudoephedrine is a "safe" ergogenic aid since it is widely available in overthe-counter cold remedies and decongestants. There are numerous reports of side effects from pseudoephedrine taken at prescribed doses, including ischemic colitis (4), stroke (3), and sudden death (5) . The NCAA does not currently have a policy regarding pseudoephedrine (15) . The recent attempts by the NCAA and the FDA to curb stimulant use appear ineffective at this point. The NCAA banned ephedrine in 1997 (11) and recently increased education efforts utilizing posters, pamphlets, and website information. It is interesting to note that over 80% of athletes in this study indicated they were aware of the NCAA ban on ephedrine, similar to the percentage in the 2003 study (1) . Only 59% of the respondents felt the national ban makes them less likely to use ephedra. Because a large percentage of college hockey athletes are foreign born, they may be less affected by this restriction as they may be able to gain access to some ergogenic aids outside the United States.
There is a perception of higher banned substance use among male athletes at their same school for players that reported use of ephedrine. This difference is statistically signifi cant. No other measured attitudes or perception of health risks vary by reported ephedrine use. Nearly 90% of athletes who admitted using ephedrine stated they began before college. We feel strongly that education efforts regarding ergogenic aids need to begin at a young age, perhaps even in grade school or middle school. The only evidence-based program found to reduce athlete use of performance-enhancing substances and drug use has been the ATLAS (athletes training and learning to avoid steroids) program (8) . This intervention study involved over 3200 high school adolescents and was a team-centered, peer-taught, and coachfacilitated intervention. In this study, new use of supplements was 50% lower among ATLAS trained athletes (8) . A similar comprehensive intervention could be modifi ed to target other performance-enhancing supplements such as stimulants.
The NCAA is responsible for the education and drug testing of college athletes (10, 15) . The current NCAA policy for drug testing includes random testing of Division I and II football and Division I track and fi eld athletes and random testing of teams in other sports that win league championships (15) . Ephedrine was added to the year-round drug testing program in 2002 (15) . Only 15% of our respondents reported being tested by the NCAA. It is evident that a more visible, credible testing program that spans all college sports may be necessary to deter use of banned substances.
There are limitations to this study. First, our study examined only one hockey conference and therefore may not be applicable to a national rate. This conference, however, is represented by teams from the Midwest, Northeast, Southeast regions and therefore may well represent the national prevalence and attitudes regarding supplements. Another potential limitation is our small sample size. The demographics of the surveyed league are very similar to other conferences throughout the U.S. We had 100% participation from the league and feel this gives excellent representation of U.S. college hockey athletes. We may be underestimating the use of stimulants due to the inherent reluctance to self-report banned substance use.
Conclusions
Almost half of college hockey athletes reported use of ephedra and/or other stimulants despite knowledge of the side effects. The NCAA ban on ephedrine and the national ban on the sale of ephedra products do not appear to have signifi cantly deterred use of stimulants in this population. The majority of athletes began use prior to college. Coaches, athletic trainers, and team physicians need to remain aware of these patterns. More effective educational efforts need to be directed at younger athletes to slow this alarming trend.
